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 ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not etanercept 
is a safe and effective treatment for ankylosing spondylitis (AS). 
 
Study Design: Review of three English language randomized control trials published in 2007, 
2008, and 2010. 
 
Data Sources: Two double-blind placebo-controlled randomized controlled trials and one 
placebo-controlled randomized control trial comparing etanercept to placebo were found using 
PubMed. 
 
Outcomes Measured: Work instability was measured through the Ankylosing Spondylitis Work 
Instability Scale (AS-WIS) based on scores of 1-20. Quality of life was measured through the 
EuroQOL-5D (EQ-5D), which assesses mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Physical functioning was evaluated through the Bath Ankylosing Spondylitis 
Functioning Index (BASFI) where scores for functional limitation range from 1-100. Lastly, the 
safety and tolerability of etanercept were assessed based on personal reports from the patients 
themselves. 
 
Results: In a study by Barkham et al, etanercept treatment was not found improve work 
instabililty but not to the point of statistical significance. Risk of job loss was also decreased in 
those who received etanercept treatment. Quality of life was considerably improved with 
etanercept therapy as seen in a RCT by Braun et al. This study also illustrated statistically 
significant improvement in physical functioning in those who obtained etanercept verse placebo. 
Long-term treatment with etanercept for 192 weeks was shown to be safe and tolerable in a study 
conducted by Davis et al. The most common adverse effect of etanercept therapy was injection 
site reaction where more reactions were present compared with placebo.  
 
Conclusions: The results of two of the randomized control trials demonstrate etanercept to be a 
safe and effective treatment for ankylosing spondylitis. One randomized control trial does not 
reach statistical significance. 
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INTRODUCTION 
 Ankylosing spondylitis (AS), one of the spondyloarthropathies, is a type of inflammatory 
arthritis that has an effect on the axial skeleton, and if severe, other parts of the body. 
Inflammation of the spinal joints can cause chronic pain and possible spinal immobility due to 
fusing of vertebrae over time.1 Ankylosing spondylitis affects men two to three times more than 
women and greatly impacts one’s quality of life. There is no current cure for AS; however, many 
drugs and therapies have been studied for symptom reduction, pain control and improvement of 
quality of life.2 This paper assesses three randomized control trials evaluating the effectiveness 
and safety of etanercept (Enbrel®) as a treatment for AS. 
 Although AS only affects 0.25% of the population, it is of importance to Physician 
Assistant practice due to the impact the disease can have on a person’s life.  Low back pain is 
one of the most frequent reason for a visit to a primary care physician, and 5% of those 
presenting with this pain have a spondyloarthropathy present.3 Low back pain is often the 
presenting complaint of those with AS. Another frequent finding among those with AS is the 
gene protein Human Leukocyte Antigen (HLA)-B27 which is seen in 7% of the US population. 
This gene protein is present in 90% of persons with AS.2 Knowledge of this frequent finding 
allows the Physician Assistant to be able to help reduce the patient’s chronic pain and systemic 
effects, slow down eventual immobility, and improve quality of life. An average of $6,720 is 
spent on each of the estimated 30,000 AS patients who visit their primary physicians each 
year.4,5 
 The precise cause of AS is unknown, but genetics are thought to play a role with the gene 
protein HLA-B27. Ankylosing spondylitis can be present without HLA-B27 due to a possible 
immune-mediated reaction pathogenesis, because environmental factors or bacterial infections 
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(especially gastrointestinal) can prompt AS in those inclined. Tumor necrosis factor (TNF)-α, 
TH17 T cells, CD4+ and CD8+ T cells, macrophages, and abundant transforming growth factor 
(TGF)-β are all thought to play a role in this immune-mediated reaction.2 Ankylosing spondylitis 
usually presents around 20-30 years of age and begins with complaints of low back pain. Acute 
painful flare-ups and remissions characterize AS, and involvement of bilateral sacroiliac joints is 
a hallmark feature.6 A diagnosis of AS is based on many factors since there is no specific 
diagnostic criteria for it. The patient may have pain upon palpation of the spine and sacroiliac 
joints and a positive Schober test: stretching of the skin upon spinal flexion of less than 15 cm 
between the sacral dimples and 10 cm above that.6 Anterior uveitis is the most common extra-
articular manifestation of AS affecting 1/3 of the patients at least once.1 Other manifestations of 
AS are peripheral arthritis, enthesitis around the pelvis and calcaneus, inflammatory bowel 
disease, and decreased chest expansion.6 
 Treatment for AS should always begin with non-steroidal anti-inflammatory drugs 
(NSAIDs). NSAIDs have been shown to improve range of motion and decrease pain, allowing 
for better daily functioning.2 All patients with AS should be involved in a physical therapy 
exercise program to help maintain posture and further improve mobility. Anti-TNF α therapy 
such as infliximab, adalimumab, and golimumab has shown to have a positive impact on 
symptom reduction and slowing disease progression and is another form of treatment commonly 
used. Surgery is a last resort treatment for those not responding to any other form of therapy. 
Common surgeries performed are total hip arthroplasties and spinal osteotomy with fixation.6 
 Symptom control has been the main aim for treatment through NSAIDs and exercise. 
Etanercept (Enbrel), an anti-TNF α drug commonly used for treatment of rheumatoid arthritis, 
has been revealed to both rapidly suppress disease activity and decrease symptoms in those with 
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AS.7,8 Improving symptoms when other treatment options have failed can greatly increase one’s 
quality of life. 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not etanercept is a safe 
and effective treatment for ankylosing spondylitis. Previous randomized control trials have 
determined etanercept as both a safe and effective treatment for ankylosing spondylitis. 
METHODS 
 Specific selection criteria of three randomized control trials (RCT) were used for this 
review. One of these RCTs was an open label extension (OLE). The population chosen was 
patients (both men and women) > 18 years of age with ankylosing spondylitis. The interventions 
utilized in each RCT were either etanercept 25mg subcutaneously twice per week7,9 or etanercept 
50mg subcutaneously once per week8. Comparisons were made between 25mg or 50mg 
etanercept to a placebo. Outcomes measured in each study were all based on patients oriented 
evidence that matters (POEMs). One outcome is change in work instability which is defined as 
“a state in which the consequences of a mismatch between an individual’s functional abilities 
and the demands of his or her job can threaten continuing employment if not resolved”.7 Quality 
of life including physical functioning, vitality, social functioning, mental health, physical and 
emotional role limitations, bodily pain, general health, and fatigue was also assessed.8 Lastly, 
safety associated with adverse events and tolerability of etanercept were measured.9 
 Key words used in the searches were “etanercept” and “ankylosing spondylitis”. All 
articles search were published in peer-reviewed journals and in the English language. The author 
researched the studies through PubMed and selected the articles based on POEMs. Inclusion 
criteria consisted of studies that were randomized control trials published after 1996 with 
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participants over the age of 18 years old. Exclusion criteria included articles with disease-
oriented evidence (DOE), published before 1996, or with participants under the age of 18 years 
old. The statistics used in the studies were 95% confidence intervals (CI), ANCOVA, ANOVA, 
Fisher’s exact test, and χ2 analyses all converted into p-values.  
OUTCOMES MEASURED 
 Outcomes measured were based on scales or actual patient reports. Work instability was 
measured through the Ankylosing Spondylitis Work Instability Scale (AS-WIS), which measures 
the risk of job loss on a scale of 1-20. Low risk scores are those <11, medium risk ranges from 
11-18, and high risk is 19-20.7 Quality of life was assessed by the EuroQOL-5D (EQ-5D) which 
includes five aspects of health such as mobility, self care, usual activities, pain/discomfort, and 
anxiety/depression.8 Included in quality of life is vitality, social functioning, mental health, 
physical and emotional role limitations, bodily pain, general health, and fatigue. The Bath 
Ankylosing Spondylitis Functional Index (BASFI) was used to measure physical functioning 
based on 10 different daily functioning questions each with a Likert scale ranging from 1 (easy) -
10 (impossible) on each question. The highest score possible is 100, which means the physical 
functioning is severely impacted. Some questions included are “Bending from the waist to puck 
up a pen from the floor without aid” and “standing unsupported for 10 minutes without 
discomfort”.10 Safety and tolerability of etanercept were both measured based on actual reports 
of patients participating in the study. 
RESULTS 
The three randomized control trials in this systematic review compared etanercept to 
placebo. Two of the studies were 12-week experimentations (Barkham, Braun) and one was 192 
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weeks (Davis). Patients in each study were allowed to continue on a steady dose of disease-
modifying antirheumatic drugs (DMARDs) and NSAIDs. DMARDs permitted in all three were 
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Pts 
Age (yrs) Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Barkham, 
20104 
RCT 40 Placebo 
mean- 
39.4; 
Etanercept 
mean- 40.8 
Patients 
currently 
working with 
active AS, 
but were 
unstable at 
work with an 
AS-WIS >10 
Past or current 
tuberculosis, 
congestive 
heart disease, 
or treatment in 
the preceding 
month with 
glucocorticoids 
0 Randomized to 
receive 25mg 
etanercept or 
placebo 
subcutaneously 
2x/week for 12 
weeks 
Braun, 
20075 
RCT 361 18-70 Patients with 
active AS 
and morning 
stiffness >30 
according to 
the visual 
analog scale 
along with 2 
of the 
following: 
VAS for 
assessment 
of disease 
activity or 
nocturnal and 
total pain 
>30; BASFI 
>30 
Patients 
previously 
exposed to 
TNF-α 
inhibitors 
5 Randomized to 
receive 50mg 
etancercept 
1x/week or 
placebo 
Davis, 
20086 
RCT 
(OLE) 
277 Mean- 41.6 Patients with 
active AS 
previously 
enrolled in a 
RCT, who 
chose to 
continue on 
with an 
open-label 
extension 
Patients 
previously 
treated with an 
anti-TNF 
besides 
etanercept 
131 Randomized to 
receive 25mg 
etanercept 
subcutaneously 
2x/week for the 
first 72 weeks, 
then 50mg 
etanercept in two 
doses of 25mg 
subcutaneously 
1x/week or 
placebo 
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methotrexate and sulfasalazine, while hydroxychloroquine was only allowed in Braun and Davis’ 
experiments. Corticosteroids begun two weeks proceeding to enrollment were acceptable in both 
Braun and Davis’ studies.  
 In the study by Barkham et al, all 40 participants remained throughout the 12 weeks. No 
statistical significance was found with overall AS-WIS scores (p=0.160); however, there was 
improvement of scores with a 95% CI with a mean decrease of 2.75 in the etanercept group 
compared to a decrease of 0.68 in placebo (table 2).7 Table 3 shows risk of job loss, where there 
was a greater decrease in the risk of job loss for the etanercept group of 55% contrasted to the 
placebo group who had only 35% decrease.7 The relative risk reduction (RRR) was calculated to 
be 57.1% and absolute risk reduction (ARR) was 20%. Numbers needed to treat (NNT) was 
calculated as 5, meaning 5 people need to be treated with etanercept in order to prevent one 
person from work instability with AS. 
Table 2: Changes in AS-WIS scores in those who received etanercept verse placebo 
Treatment Group Mean AS-WIS decrease 
Etanercept -2.75 
Placebo -0.68 
 
Table 3: Risk of job loss 
CER EER RRR ARR NNT p-value 
35% 55% 57.1% 20% 5 0.160 
 
 The study conducted by Braun et al was based on modified intention to treat where the 
population includes patients who received at least one dose of etanercept or placebo. There were 
356 participants who made up this population, and 321 completed the study (90%).  At the 
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beginning of the study, a large number of patients reported issues in the 5 aspects of the EQ-5D 
scale: 79.8% reported problems with mobility, 89.9% with usual activities, 64.6% admitted to 
anxiety/depression, 57% had problems with self care, and 99.2 reported pain or discomfort. 
Statistically significant improvements (p<0.01) in all the EQ-5D categories were reported. After 
12 weeks of treatment, 66% of etanercept patients had clinical benefit with improvement 
compared to 50% of those with placebo as shown in table 4.8 The relative benefit increase (RBI) 
was calculated to be 32% and absolute benefit increase (ABI) was 16%. NNT was calculated as 
2, meaning 2 people need to be treated with 50mg etanercept once a week for 12 weeks in order 
to improve 1 person’s quality of life compared to control. Statistically significant improvements 
in the etanercept group were also seen with the BASFI from weeks 2-12 (table 5). At week 2, the 
BASFI score decreased by 15 (p<0.05), week 4 by about 22 (p<0.001), week 8 about 25 
(p<0.0001), and by week 12 the score decreased by approximately 27 (p<0.0001). No 
statistically significant difference in the BASFI was seen with the placebo group: week 2 score 
decreased about 7 and weeks 4-12 had a decrease of roughly 10.8 
Table 4: Benefit of etanercept on improvement in EQ-5D 
CER EER RBI ABI NNT p-value 
50% 66% 32% 16% 2 P<0.01 
 
Table 5: Improvement in BASFI scores in etanercept group compared to placebo 
Group Week 2 Week 4 Week 8 Week 12 
Etanercept -15 (p<0.05) -22 (p<0.001) -25 (p<0.0001) -27 (p<0.0001) 
Placebo -7 -10 -10 -10 
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 The study by Davis et al was an open label extension (OLE) of 168 weeks from a 24-
week experiment. There were 277 participants in the original study and 257 continued with the 
OLE. Of these 257 participants, 129 received placebo and 128 received 50mg etanercept once a 
week. Only 126 of these patients went on to complete the entire course of the experiment, 
accounting for a 49% loss. The majority of losses were due to patient refusal, followed by 
adverse effects, lack of efficacy, lost to follow-up, protocol violation, protocol requirement, and 
lastly physician decision. Etanercept 50mg once per week was given to everyone for the 168 
weeks of the OLE. Treatment with etanercept over 192 weeks was overall found to be safe. 
Results were compared to the placebo group from the original RCT (table 6). The most common 
adverse event was injection site reactions (ISR), and from the original 257 enrolled in the OLE, 
57 (22.2%) reported an ISR. Of the 139 who received placebo in the RCT, 13 (9.4%) reported an 
ISR.9 The relative risk increase (RRI) calculated was 139% and absolute risk increase (ARI) was 
12.8%. Numbers needed to harm (NNH) was 8 meaning for every 8 people treated with 
etanercept for 192 weeks, 1 person will be harmed with an ISR compared to control. Table 7 
shows other adverse events of long-term etanercept treatment. Serious adverse events were only 
reported from 33 participants (12.8%) with depression being the most common (1.2%). 
Infections were also common in those treated with etanercept and developed in 187 (72.8%) 
participants compared to 43 (30.9%) with placebo. The most common infections were upper 
respiratory infections (45%) and sinusitis (16%). No deaths were reported from this study.9 
Table 6: Harms from injection site reactions of those treated with 192 weeks etanercept 
compared to 24 weeks placebo 
CER EER RRI ARI NNH 
9.4% 22.2% 139% 12.8% 8 
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Table 7: Adverse events of long-term etanercept treatment compared to placebo 
 ISR Infections Serious 
Adverse 
Events 
Depression Death 
Etanercept 57 
(22.2%) 
187 (72.8) 
URI: 45% 
Sinusitis: 16% 
33 (12.8%) 3 (1.2%) 0 
Placebo 13 
(9.4%) 
43 (30.9%) 4 (2.9%) Not 
Reported 
0 
 
DISCUSSION 
 This systematic review investigated the three RCTs for the safety and effectiveness of 
etanercept as a treatment for AS. The studies by Braun et al and Davis et al demonstrated this 
drug as a safe and effective treatment. Statistical significance was not reached in the study 
conducted by Barkham et al; however, a relatively beneficial NNT of 5 still allows for some 
efficacy. 
Ankylosing spondylitis is a progressive disease with no current cure that can eventually 
develop into immobility, so treatment to improve the lives of these patients is important. 
Etanercept has been established to be a safe way to improve the quality of life and daily 
functioning of those with AS. This drug has also been FDA approved for the treatment of 
moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and 
moderate to severe chronic plaque psoriasis.11 Although etanercept is an expensive drug, 
insurance companies work with the patient to cover most if not all of the cost. There is currently 
no generic available in the U.S. An ENBREL supportTM Card is also available to provide 
assistance for eligible patients in need.11,12 Contraindications to treatment include a previous 
hypersensitivity reaction to the drug or any part of its formulation and any individual with sepsis. 
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It is also important not to administer live vaccines while undergoing treatment.11 Boxed warnings 
for infections and malignancy are currently in place due to adverse events that have been seen in 
those using etanercept. Severe infections including tuberculosis, invasive fungal, bacterial, viral, 
and opportunistic infections have been noted, and lymphoma and other malignancies have been 
seen in children.11 
There were various limitations among the studies presented in this review. A small 
sample size of 40 participants in the Barkham et al study may not have been sufficient enough 
for a proper representation of the AS population. The Davis et al study was carried out for an 
exceedingly long period of time, which may be a major contribution to the 51% participant loss 
by the end of the 192 weeks. For all three studies, results may have been impacted by a variation 
in occupations, daily activities, and lifestyles of each participant. 
CONCLUSION 
 Etanercept is a safe treatment for AS and effective for improving quality of life and 
physical functioning as revealed by this review. Effectiveness for work instability was seen, but 
not enough to prove statistical significance. Future studies on work instability should be 
performed with participants who have the same or similar occupation. Another direction for 
future research should be aimed at a way to reduce adverse events associated with etanercept 
treatment. Anti-TNF α therapy is becoming more widely used among the AS population. It 
would be beneficial so determine the differences in outcomes between etanercept and other 
commonly used Anti-TNF α drugs such as infliximab, adalimumab, and golimumab. Continuing 
research on treatment for AS should provide those with the disease an opportunity to live a less 
painful and debilitating life.
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